Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT ID: NCT03941379 Phase: N/A Sponsor: Aura Biosciences Status: Active Not Recruiting

SUMMARY

The purpose of this observational research study is to follow participants who have been treated with bel-sar while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. The study will collect information based on assessments performed as part of the standard of care (SoC) for subjects with IL/CM, inclusive of all adverse events, concomitant medications and/or procedures, information regarding metastatic disease and details of treatments administered, and information about melanoma-related and all-cause mortality and cause of death (if applicable).

KEY ELIGIBILITY CRITERIA

- * Have been clinically diagnosed with primary IL or CM at the time of entry to a previous Aura Biosciences sponsored clinical trial.
- * Have received AU-011 bel-sar treatment in a previous Aura Biosciences sponsored clinical trial.
- * Have completed the exit visit of the previous Aura Biosciences sponsored clinical trial within 1 year of Day 1 (d365 days) of enrollment into the Registry.

Total sites: 16 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT03941379) and public sources. Generated by FindMyCure.ai.